What Piramal Group does

Piramal Group is a Mumbai-headquartered diversified Indian conglomerate founded in 1912 and publicly listed on the NSE under ticker PEL, operating across three core business verticals: Piramal Finance, Piramal Pharma Limited, and Piramal Realty. Under Chairman Ajay Piramal, the group has transformed from its textile origins into a multi-business platform operating in 30+ countries and 100+ markets with 10,000+ employees. Piramal Finance is a digital-first NBFC that serves India's underserved individuals, micro-entrepreneurs, and families through retail lending, affordable housing finance, and MSME products distributed across 13,000+ pin codes; the business was fundamentally reshaped by the landmark 2021 acquisition of Dewan Housing Finance Corporation for Rs 34,250 crore under IBC resolution. Piramal Pharma Limited operates as a global contract development and manufacturing organization (CDMO) through 17 facilities serving 100+ countries, with capabilities spanning API manufacturing, formulation development, antibody drug conjugates (ADC), advanced flow reactors, biocatalysis, and clinical trial supplies, targeting a doubling of turnover to $2 billion by 2030. Piramal Realty develops residential and commercial properties in the Mumbai Metropolitan Region, with 13 million sq. ft. delivered and approximately 11 million sq. ft. under development. The group also operates Piramal Alternatives for alternative investments (private equity, credit, and real estate), the India Resurgence Fund (IndiaRF) joint venture with Bain Capital focused on distressed-asset resolution (including the Rs 1,650 crore Synthimed Labs carve-out from Ind-Swift Laboratories), and the Piramal Foundation, which has impacted 112-143 million Indian lives across healthcare, education, and nutrition.

The group's underlying technology and digital backbone is anchored by Project Catalyst NxGen, an enterprise-wide ERP and digital transformation programme integrating AI-driven automation, advanced analytics, and infrastructure modernization across Piramal Pharma's manufacturing, quality, supply chain, and R&D operations, with stated outcomes including improved on-time-in-full delivery, reduced unplanned downtime, faster batch release cycles, and a single source of truth for enterprise decision-making. Piramal Group's revenue model is a hybrid of NBFC interest income and processing fees (Piramal Finance), project-based and recurring CDMO contracts (Piramal Pharma), one-time property sales (Piramal Realty), and transaction/management fees from alternative investment vehicles (Piramal Alternatives and IndiaRF). Go-to-market motions are vertically distinct: digital-first retail lending with field relationships for finance, direct B2B sales to global pharma and biotech for pharma CDMO, and direct developer-led sales for real estate. Ownership remains family-controlled, with the second generation (Nandini Piramal as Chairperson of Piramal Pharma and Anand Piramal as Chairman of Piramal Finance and Executive Director of Piramal Realty) leading operational subsidiaries alongside the Chairman, supported by a professional management team including Jairam Sridharan (MD & CEO, Piramal Finance) and Peter DeYoung (CEO, Piramal Global Pharma).

Name

Piramal Group

Legal name

Piramal Enterprises Limited

Website

https://piramal.com

Company type

Private

Founded year

1912

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Piramal Group is a diversified Indian conglomerate operating across three core verticals: Piramal Finance (digital-first NBFC serving 5M+ underserved borrowers), Piramal Pharma (global CDMO with 17 facilities across 100+ countries), and Piramal Realty (MMR residential developer with 13M sq. ft. delivered). It also manages Piramal Alternatives (PE/credit) and the IndiaRF joint venture with Bain Capital.

Ownership category

akta.pro rank

Product category

Diversified Conglomerate

NAICS

Management of Companies and Enterprises (5511), Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282), Real Estate Dealers (For Their Own Account) (6532)

akta.pro primary industry

General SME & Middle-Market Commercial Banking (FSABABAA)

akta.pro secondary industry

Real Estate Strategy & Portfolio Consulting (Corporate/Institutional) (BPAJANAB)

Keywords

• Pharmaceutical contract manufacturing
• Non-banking financial services
• Real estate development
• Alternative asset management
• Pharmaceutical research services

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Financial Services (NBFC) — Piramal Finance / Piramal Alternatives: Piramal Finance operates as an NBFC providing loans to underserved individuals, micro-entrepreneurs, and families for affordable housing and MSMEs. Piramal Alternatives manages alternative investment vehicles including the India Resurgence Fund (IndiaRF), a JV with Bain Capital, investing in distressed assets and growth opportunities. Revenue generated through interest income, processing fees, and fund management fees.
2. Pharmaceutical CDMO — Piramal Pharma Solutions: Contract Development and Manufacturing Organization (CDMO) providing custom research and manufacturing services to global pharma and biotech companies. Services span API manufacturing, formulation development, clinical trial supplies, and commercial manufacturing. Revenue model is project-based and transactional, with long-term client contracts providing recurring engagement.
3. Real Estate Development — Piramal Realty: Residential and commercial real estate development in the Mumbai Metropolitan Region. Revenue generated through property sales. Piramal Realty has developed over 13 million sq. ft. across residential and commercial projects, with over 4,200 homes delivered and approximately 11 million sq. ft. under development.
4. Asset Resolution / Distressed Investing: Through India Resurgence Fund (IndiaRF), Piramal manages distressed asset resolution including the acquisition and resolution of Dewan Housing Finance Corporation (DHFL). Revenue derived from asset recovery, management fees, and performance carry.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Core offering

Piramal Group is a diversified Indian conglomerate operating three core businesses: Piramal Finance, a non-banking financial company providing retail and wholesale lending across 13,000+ Indian pin codes; Piramal Pharma Limited, a global pharmaceutical contract development and manufacturing organization (CDMO) operating 17 facilities serving customers in 100+ countries with capabilities across complex APIs, formulations, antibody drug conjugates, and biologics; and Piramal Realty, a residential real estate developer in the Mumbai Metropolitan Region. Supporting businesses include Piramal Alternatives for alternative asset management and the Piramal Foundation for philanthropic activities.

Product overview

Piramal Group is a diversified Indian conglomerate operating across three core business segments: Financial Services (Piramal Finance - a digital-first NBFC serving underserved communities), Pharmaceuticals (Piramal Pharma Limited - a global CDMO offering contract manufacturing and R&D services), and Real Estate (Piramal Realty - residential and commercial development in Mumbai). The group also operates Piramal Alternatives for alternative investments and Piramal Foundation for philanthropy. The portfolio companies work synergistically under the Group's 'Doing Well and Doing Good' philosophy, with financial services and pharma being the primary growth engines targeting FY2030 goals of doubling revenue and tripling profitability.

Differentiator

Problem solved

Functional benefit

Brands

• Piramal Finance: Digital-first financial services NBFC serving India's underserved individuals, micro-entrepreneurs, and families with accessible financial solutions. Present in over 13,000 pin codes.
• Piramal Pharma Limited
• Piramal Realty
• Piramal Alternatives
• Piramal Foundation

Products and services

• Piramal Finance (NBFC lending) Non-banking financial services (NBFC) offering retail, housing, MSME, and wholesale lending products, with a stated focus on financial inclusion and serving underserved retail and small-business customers across 13,000+ Indian pin codes through a hybrid digital and physical distribution model.
• Piramal Pharma Limited (CDMO services) Global pharmaceutical contract development and manufacturing organization (CDMO) providing services for complex APIs, formulations, antibody drug conjugates, biologics, and peptide platforms, operating 17 facilities across multiple geographies and serving customers in 100+ countries.
• Piramal Realty (residential real estate development) Premium residential real estate developer in the Mumbai Metropolitan Region, developing branded housing projects under the Piramal name for end-user homebuyers in the premium and upper-middle-class segments.
• Piramal Alternatives (alternative asset management) Alternative asset management platform offering India-focused private credit, distressed asset, and special situations investment strategies for institutional and high-net-worth investors, including the India Resurgence Fund joint venture with Bain Capital.

Quantifiable outcome

• Piramal Finance has provided over 5 million customers with loans, including 2.5 million+ life-changing loans to underserved communities for affordable housing and MSMEs
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

Five partnerships are on record, tiered minor and core.

• India Leaders for Social Sector (ILSS)minorStrategic or Co-development Partner · 5 February 2026Piramal Group Chairman Ajay Piramal spoke at the India Fundraising Conference organized by India Leaders for Social Sector in Delhi, which marked the launch of India's first dedicated Fundraisers' Network (TFN), aimed at unlocking capital and enabling collaboration across the social sector.
• NewAmsterdam PharmacoreStrategic or Co-development Partner · 22 August 2025Piramal Pharma Solutions and NewAmsterdam Pharma invested in a dedicated suite to enhance oral solid dosage production capabilities at Piramal's Sellersville, Pennsylvania site, co-investing in manufacturing infrastructure for a strategic pharmaceutical partnership.
• Catalyst Management Services (CMS)coreStrategic or Co-development Partner · 13 September 2024Catalyst Management Services (CMS) partnered with Piramal Foundation to advance the Ayushman Digital Bharat Mission, combining CMS's management capabilities with Piramal Foundation's social impact expertise in healthcare and digital inclusion.
• Sri Lanka CricketminorGTM or Marketing Partner · 2 August 2024Piramal Finance collaborated with Sri Lanka Cricket for marketing and brand visibility purposes, extending the financial services brand's reach through sports sponsorship.
• Synthimed LabscoreStrategic or Co-development Partner · 1 January 2024Synthimed Labs was established in March 2024 as a special purpose vehicle to house the carved-out generic API and CRAMS business acquired from Ind-Swift Laboratories for ₹1,650 crore, under IndiaRF portfolio. Reported revenues of ₹1,452 crore with EBITDA of ₹469 crore in FY25.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Tata Group: India's flagship diversified conglomerate with operations across IT (TCS), manufacturing (Tata Motors), consumer (Titan), and financial services. Comparable as an Indian multi-vertical conglomerate with global footprint.
• Reliance Industries: India's largest diversified conglomerate spanning energy, retail, telecom (Jio), and financial services. Comparable as a broad Indian conglomerate with multiple scaled operating pillars, though much larger in market cap.

Direct peers

• Cholamandalam Investment and Finance: Indian NBFC focused on vehicle finance, home loans, and MSME lending. Comparable to Piramal Finance on retail NBFC model, MSME focus, and digital-led distribution.
• Bajaj Finance: India's largest retail-focused NBFC serving consumers, SMEs, and merchants. Directly comparable to Piramal Finance on retail lending scale, customer base growth, and MSME/unsecured lending strategy.
• Oberoi Realty: Mumbai-focused premium residential and commercial developer. Closest direct peer to Piramal Realty in MMR luxury segment with comparable product positioning and design-led approach.
• Divi's Laboratories: Indian API manufacturer with significant exposure to custom synthesis and generics. Comparable to Piramal Pharma on API manufacturing scale, global pharma customer base, and CRAMS exposure.
• Godrej Group: Indian diversified conglomerate with parallel exposure to consumer products, real estate (Godrej Properties), and financial services. Closest structural comparable to Piramal in terms of multi-vertical Indian family-led conglomerate model.
• Macrotech Developers (Lodha): Largest Mumbai-based residential real estate developer with similar premium/mid-market positioning and scale. Directly comparable to Piramal Realty on geography (MMR), product mix, and project scale.
• Syngene International: Indian-listed CDMO providing contract development and manufacturing services to global pharma. Closest direct peer to Piramal Pharma's CDMO business in terms of offering, customer base, and growth profile.

Emerging players

• Laurus Labs: Indian pharma company with CDMO, API, and generics exposure, including emerging capability in biologics/ADC. Comparable to Piramal Pharma on the CDMO/API mix and emerging biotech customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/PiramalGroup
• Facebookfacebook.com/PiramalEnterprisesLimited
• LinkedInlinkedin.com/company/piramalgroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries6 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Piramal Group